Tilray (NASDAQ: TLRY) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare Tilray to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Insider and Institutional Ownership

10.4% of Tilray shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Tilray has a beta of 2.92, meaning that its stock price is 192% more volatile than the S&P 500. Comparatively, Tilray’s competitors have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Tilray and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray 1 12 2 0 2.07
Tilray Competitors 133 357 403 14 2.33

Tilray currently has a consensus target price of $12.91, indicating a potential upside of 169.50%. As a group, “Medicinals & botanicals” companies have a potential upside of 114.70%. Given Tilray’s higher probable upside, equities research analysts plainly believe Tilray is more favorable than its competitors.

Earnings & Valuation

This table compares Tilray and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tilray $166.98 million -$321.17 million -2.83
Tilray Competitors $219.25 million -$99.48 million 2.53

Tilray’s competitors have higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Tilray and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tilray -259.60% -77.77% -21.45%
Tilray Competitors -1,150.45% -258.05% -48.97%


Tilray competitors beat Tilray on 8 of the 13 factors compared.

Tilray Company Profile

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.